CSR&D Research Career Development Transition Award Application

本申请是职业发展过渡奖(CDTA)的申请表。作为精神病学家和临床医生 作为研究员，Yoon博士设计并进行了几项临床试验和转化性研究，由 基于神经科学的假说。他的研究的主要目标是评估和开发治疗 令人上瘾的精神障碍。他是退伍军人管理局职业发展奖(CDA-2)和 功绩评审奖。Yoon博士已经测试了治疗成瘾和精神病的新方法 特别关注酒精使用障碍(AUD)和严重抑郁障碍(MDD)。许多. 他的研究首次将临床前研究中的一项新观察转化为对这些疾病的人类治疗 精神错乱。 上瘾和精神障碍会导致巨大的发病率和死亡率，而且成本非常高。 退伍军人事务部。他正在测试的药理学方法具有巨大的潜力，可以帮助患有 令人上瘾的精神障碍。他目前的功绩评估奖项目正在进行中，以评估 氯胺酮(NMDA谷氨酸受体拮抗剂)和纳曲酮(阿片受体)的联合应用 拮抗剂)在减少抑郁和饮酒方面有效。这项研究具有很高的创新性， 就(A)阿片受体刺激是否有助于抗抑郁作用提出重要问题 以及(B)纳曲酮和氯胺酮的联合使用是否可能是减少 在快速治疗抑郁症的同时有上瘾的风险。由于适当的治疗MDD和AUD具有重要的临床意义 重要的是，氯胺酮加纳曲酮的方法可能会对患者产生变革性影响 在这种情况下。 CDTA将把他的能力扩展到目前的功绩审查奖项目之外，并领导他的 作为一名临床研究人员的成长和发展。他在CDTA期间的研究计划包括：(A) 进行目前得到资助的六项临床试验(项目1-6)，(B)重新提交两项NIH R01 申请(项目7-8)和(C)提交两份新的赠款申请(项目9-10)。建立在 从这些项目的发现，他的长期目标是开发新的和更有效的药理 对成瘾和精神障碍的干预。除了这些研究活动外，他还将参加 在训练活动中。Yoon博士正在积极与退伍军人管理局和耶鲁大学的研究人员合作。他们收集了数据， 分享研究技术，发表论文，并提交拨款申请。 有三个目标。 目标1：进行目前已获得资助的6项临床试验(项目1-6)。 目标2：重新提交两个NIH R01申请(项目7-8)和提交两个新的拨款申请(项目9- 10) 目标3：参加(1)氯胺酮和精神病学研究，(2)神经科学和药物方面的培训活动 发现，(3)成瘾研究，(4)临床试验和研究方法，(5)神经成像，(6) 药物基因组学，以及(7)生物统计学。 结论：CDTA将保护尹博士的研究、培训和活动发展得更有效 成瘾和精神障碍的治疗。

This application is for the Career Development Transition Award (CDTA). As a psychiatrist and clinical researcher, Dr. Yoon has designed and conducted several clinical trials and translational research driven by neuroscience-based hypotheses. The main goal of his research is to evaluate and develop medications for addictive and psychiatric disorders. He is a recipient of the VA Career Development Award (CDA-2) and the Merit Review Award. Dr. Yoon has tested novel approaches for the treatment of addictive and psychiatric disorders, particularly focusing on alcohol use disorder (AUD) and major depressive disorder (MDD). Many of his studies are the first to translate a novel observation in preclinical research to human therapy for these disorders. Addictive and psychiatric disorders produce enormous morbidity and mortality, and are very costly to the VA. The pharmacological approach he is testing has enormous potential to help patients suffering from addictive and psychiatric disorders. His current Merit Review award project is being conducted to evaluate whether the combination of ketamine (NMDA glutamate receptor antagonist) and naltrexone (opioid receptor antagonist) is effective in reducing depression and alcohol consumption. This study is highly innovative by asking important questions on (a) whether opioid receptor stimulation contributes to the antidepressant effects of ketamine and (b) whether the combination of naltrexone and ketamine might be a strategy to reduce addiction risk while rapidly treating depression. Since adequate treatment of MDD and AUD is of major clinical importance, the ketamine plus naltrexone approach may have a transformative impact on patients suffering from this condition. The CDTA will extend his capabilities beyond the current Merit Review Award project and lead his growth and development as a clinical researcher. His research plans during the CDTA period include: (a) conduct of six clinical trials that are currently funded (Project 1-6), (b) resubmission of two NIH R01 applications (Project 7-8), and (c) submission of two new grant applications (Project 9-10). Building on the findings from these projects, his long-term goal is to develop new and more effective pharmacological interventions for addictive and psychiatric disorders. In addition to these research activities, he will participate in training activities. Dr. Yoon is actively collaborating with VA and Yale researchers. They have collected data, shared research techniques, published papers, and submitted grant applications. There are three objectives. Aim #1: To conduct six clinical trials that are currently funded (Project 1-6). Aim #2: To resubmit two NIH R01 applications (Project 7-8) and submit two new grant applications (Project 9- 10) Aim #3: To participate in training activities in (1) ketamine and psychiatric research, (2) neuroscience and drug discovery, (3) addiction research, (4) clinical trials and research methodology, (5) neuroimaging, (6) pharmacogenomics, and (7) biostatistics. Conclusion: The CDTA will protect Dr. Yoon’s research training and activity to develop more effective treatments for addictive and psychiatric disorders.